HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
RecruitingNCT06778564

Cannabidiol added to antipsychotic treatment after a first psychosis episode

About this titleRead the official source — NCT06778564
Medication studyAges 16–40Multiple countriesSchizophrenia
The study in practice

Understand this study

Who could participate?

Listed age limits: 16 years to 40 years.

What will I do during this study?

Participants are randomly assigned to six weeks of cannabidiol or placebo (an inactive comparison treatment) alongside their existing antipsychotic treatment. The study focuses on people experiencing a first episode of psychosis whose response to initial treatment has been limited.

Listed locations
Vienna and 16 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: October 5, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
250
Sponsor
University of Oxford
Sponsor type
University
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United Kingdom, Switzerland, Austria, ...
Age range
From 16 Years to 40 Years
Official registry ID
NCT06778564
Official title
Show the full official title

Augmentation With Cannabidiol in First Episode Psychosis: a Double-blind, Randomised Controlled Trial

Recruitment & locations

Currently recruiting

Vienna, Austria · Augsburg, Germany · Berlin, Germany

14 more locations
  • Cologne, Germany
  • Munich, Germany
  • Athens, Greece
  • Hod HaSharon, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Naples, Italy
  • Amsterdam, Netherlands
  • Madrid, Spain
  • Seville, Spain
  • Zurich, Switzerland
  • Cambridge, United Kingdom
  • London, United Kingdom
  • Oxford, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Oxford, a university.

Does this study involve medication?

Yes. The study involves medication, including CBD 100 mg/mL Oral Solution.

Who can participate?

Listed age limits: 16 years to 40 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies